Biotech · Private company
Seagen, a wholly owned subsidiary of Pfizer
Track this companyFree. Adds Seagen, a wholly owned subsidiary of Pfizer to your Dealase workspace and tells you when its record changes.
Clinical trials2516 recruiting or active
Pipeline programs62From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline62
- bevacizumabPhase 3 · Colorectal NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- Brentuximab vedotinPhase 3 · Diffuse Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- carboplatinPhase 3 · Urothelial CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- cetuximabPhase 3 · Colorectal NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- cisplatinPhase 3 · Urothelial CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Combination product: Trastuzumab + PertuzumabPhase 3 · HER2 Positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- disitamab vedotinPhase 3 · Urothelial CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- docetaxelPhase 3 · Carcinoma, Non-Small-Cell LungClinicalTrials.gov · fetched Nov 12, 2026
- gemcitabinePhase 3 · Urothelial CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- LenalidomidePhase 3 · Diffuse Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- leucovorinPhase 3 · Colorectal NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- oxaliplatinPhase 3 · Colorectal NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- pembrolizumabPhase 3 · Urothelial CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- PertuzumabPhase 3 · HER2 Positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- RituximabPhase 3 · Diffuse Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- sigvotatug vedotinPhase 3 · Carcinoma, Non-Small-Cell LungClinicalTrials.gov · fetched Nov 12, 2026
- T-DM1Phase 3 · HER2-positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- trastuzumabPhase 3 · Colorectal NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- TrastuzumabPhase 3 · HER2 Positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- tucatinibPhase 3 · Colorectal NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- TucatinibPhase 3 · HER2 Positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- BevacizumabPhase 2 · Cervical CancerClinicalTrials.gov · fetched Nov 12, 2026
- brentuximab vedotinPhase 2 · Peripheral T-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- brentuximab vedotinPhase 2 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- capecitabinePhase 2 · Colorectal CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- carboplatinPhase 2 · Colorectal NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- CarboplatinPhase 2 · Cervical CancerClinicalTrials.gov · fetched Nov 12, 2026
- cisplatinPhase 2 · Colorectal NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- cyclophosphamidePhase 2 · Peripheral T-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- disitamab vedotinPhase 2 · Breast NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- disitamab vedotinPhase 2 · Carcinoma, Non-Small-Cell LungClinicalTrials.gov · fetched Nov 12, 2026
- doxorubicinPhase 2 · Peripheral T-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- fluorouracilPhase 2 · Colorectal CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- fulvestrantPhase 2 · Uterine NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- leucovorinPhase 2 · Colorectal CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- oxaliplatinPhase 2 · Colorectal CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- pembrolizumabPhase 2 · Colorectal NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- pembrolizumabPhase 2 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Cervical CancerClinicalTrials.gov · fetched Nov 12, 2026
- prednisonePhase 2 · Peripheral T-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- tisotumab vedotinPhase 2 · Colorectal NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- Tisotumab VedotinPhase 2 · Cervical CancerClinicalTrials.gov · fetched Nov 12, 2026
- trastuzumabPhase 2 · Colorectal CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- trastuzumabPhase 2 · Uterine NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- tucatinibPhase 2 · Uterine NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- tucatinibPhase 2 · Colorectal CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- tucatinibPhase 2 · Breast NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- 5-Fluorouracil (5-FU)Phase 1 · Colorectal NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- azacitidinePhase 1 · Myelodysplastic SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- carboplatinPhase 1 · Carcinoma, Non-Small Cell LungClinicalTrials.gov · fetched Nov 12, 2026
- cisplatinPhase 1 · Carcinoma, Non-Small Cell LungClinicalTrials.gov · fetched Nov 12, 2026
- Leucovorin (LV)Phase 1 · Colorectal NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- pembrolizumabPhase 1 · Carcinoma, Non-Small-Cell LungClinicalTrials.gov · fetched Nov 12, 2026
- PF-08046044/SGN-35CPhase 1 · Hodgkin DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- PF-08046045Phase 1 · Lymphoma, T-Cell, CutaneousClinicalTrials.gov · fetched Nov 12, 2026
- PF-08046049Phase 1 · Cutaneous MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- PF-08046050Phase 1 · Colorectal NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- PF-08046052Phase 1 · Colorectal NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- PF-08046054Phase 1 · Carcinoma, Non-Small-Cell LungClinicalTrials.gov · fetched Nov 12, 2026
- PF-08052666Phase 1 · Carcinoma, Non-Small-Cell LungClinicalTrials.gov · fetched Nov 12, 2026
- SEA-CD70Phase 1 · Myelodysplastic SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- VenetoclaxPhase 1 · Myelodysplastic SyndromeClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- A Study of SGN-MesoC2 in Advanced Solid TumorsPHASE1 · TERMINATED · started Aug 2, 2024ClinicalTrials.gov NCT06466187 · fetched Nov 12, 2026
- A Safety Study of PF-08046044/SGN-35C in Adults With Advanced CancersPHASE1 · TERMINATED · started May 28, 2024ClinicalTrials.gov NCT06254495 · fetched Nov 12, 2026
- A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid TumorsPHASE2 · ACTIVE_NOT_RECRUITING · started May 20, 2024ClinicalTrials.gov NCT06157892 · fetched Nov 12, 2026
- A Safety Study of PF-08046045/SGN-35T in Adults With Advanced CancersPHASE1 · TERMINATED · started Feb 29, 2024ClinicalTrials.gov NCT06120504 · fetched Nov 12, 2026
- A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung CancerPHASE3 · ACTIVE_NOT_RECRUITING · started Feb 21, 2024ClinicalTrials.gov NCT06012435 · fetched Nov 12, 2026
- A Study of SGN-CEACAM5C in Adults With Advanced Solid TumorsPHASE1 · RECRUITING · started Nov 20, 2023ClinicalTrials.gov NCT06131840 · fetched Nov 12, 2026
- A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid TumorsPHASE1 · TERMINATED · started Nov 14, 2023ClinicalTrials.gov NCT05983133 · fetched Nov 12, 2026
- A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2PHASE2 · ACTIVE_NOT_RECRUITING · started Nov 14, 2023ClinicalTrials.gov NCT06003231 · fetched Nov 12, 2026
- Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2PHASE3 · ACTIVE_NOT_RECRUITING · started Sep 22, 2023ClinicalTrials.gov NCT05911295 · fetched Nov 12, 2026
- A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid TumorsPHASE1 · TERMINATED · started Jan 3, 2023ClinicalTrials.gov NCT05571839 · fetched Nov 12, 2026
- A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsPHASE1 · RECRUITING · started Oct 25, 2022ClinicalTrials.gov NCT05208762 · fetched Nov 12, 2026
- A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal CancerPHASE3 · RECRUITING · started Oct 24, 2022ClinicalTrials.gov NCT05253651 · fetched Nov 12, 2026
- A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2PHASE2 · RECRUITING · started May 3, 2022ClinicalTrials.gov NCT04879329 · fetched Nov 12, 2026
- A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast CancerPHASE3 · ACTIVE_NOT_RECRUITING · started Mar 7, 2022ClinicalTrials.gov NCT05132582 · fetched Nov 12, 2026
- A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)PHASE1 · TERMINATED · started Dec 7, 2021ClinicalTrials.gov NCT05014139 · fetched Nov 12, 2026
- Brentuximab Vedotin With Pembrolizumab in Metastatic Solid TumorsPHASE2 · COMPLETED · started Jan 26, 2021ClinicalTrials.gov NCT04609566 · fetched Nov 12, 2026
- Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 AlterationsPHASE2 · ACTIVE_NOT_RECRUITING · started Jan 11, 2021ClinicalTrials.gov NCT04579380 · fetched Nov 12, 2026
- A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 ExpressionPHASE2 · COMPLETED · started Nov 12, 2020ClinicalTrials.gov NCT04569032 · fetched Nov 12, 2026
- Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal CancersPHASE2 · ACTIVE_NOT_RECRUITING · started Sep 15, 2020ClinicalTrials.gov NCT04430738 · fetched Nov 12, 2026
- Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCLPHASE3 · ACTIVE_NOT_RECRUITING · started Aug 20, 2020ClinicalTrials.gov NCT04404283 · fetched Nov 12, 2026
- A Safety Study of SEA-CD70 in Patients With Myeloid MalignanciesPHASE1 · ACTIVE_NOT_RECRUITING · started Aug 7, 2020ClinicalTrials.gov NCT04227847 · fetched Nov 12, 2026
- A Study of Sigvotatug Vedotin in Advanced Solid TumorsPHASE1 · RECRUITING · started Jun 8, 2020ClinicalTrials.gov NCT04389632 · fetched Nov 12, 2026
- A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast CancerPHASE3 · ACTIVE_NOT_RECRUITING · started Oct 2, 2019ClinicalTrials.gov NCT03975647 · fetched Nov 12, 2026
- Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical CancerPHASE1_PHASE2 · TERMINATED · started Feb 27, 2019ClinicalTrials.gov NCT03786081 · fetched Nov 12, 2026
- Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid TumorsPHASE2 · ACTIVE_NOT_RECRUITING · started Jun 25, 2018ClinicalTrials.gov NCT03485209 · fetched Nov 12, 2026